Skip to main content
Premium Trial:

Request an Annual Quote

NetGenics CFO Resigns to Join Phase-1 as CEO

NEW YORK, March 23 – Vincent Kazmer said Friday he was resigning as chief financial officer of NetGenics to join Phase-1 Molecular Toxicology as CEO.

“Phase-1 is a good opportunity,” Kazmer said. His resignation is effective immediately and he will start work at Phase-1 Molecular Toxicology in April.

The company, which is based in Santa Fe, NM, uses gene expression technologies and bioinformatics to help improve lead optimization and diminish toxic effects early in a drug’s development.

Phase-1’s founder Spencer Farr will head the company’s R&D division.

"As the company continues to expand its operations and business into Europe and Japan, and seeks to capitalize on the significant opportunities at hand, it is crucial to have a seasoned business leader at the helm,” Farr said.

Prior to joining NetGenics Kazmer was CEO of Lark Technologies, a publicly traded molecular biology contract research organization. 

NetGenics has not yet named a replacement for Kazmer. The Cleveland-based bioinformatics company recently laid off 29 of its 100 employees due to the downturn in the economic conditions, which forced the company to delay its IPO.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.